AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)

NEXT STORY
UPDATE — Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting
PREV STORY
Precision Therapeutics, Inc. Signs Letter of Intent to Purchase Remainder of Helomics Corporation Shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. EDTSAN DIEGO, Aug. 08, 2018 (GLOBE ...

author_avatar
NASDAQ Market News

Clinical Solutions Market has been driven by Increasing Adoption of Clinical Trials and Increase in R&D Expenditure by Pharmaceutical and Biopharmaceutical Companies like Parexel, Oracle, Veeva Systems, ERT, IBM, eClinicalWorks, Bioclinica, ICON plc, MasterControl, OmniComm Systems

author_avatar
NASDAQ Market News

Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results

PROCYSBI® Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million 2016 Non-GAAP Operating Expense ...

author_avatar
NASDAQ Market News